This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
TCR2 Therapeutics Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for TCR2 Therapeutics.
Información clave
-0.2%
Tasa de crecimiento de los beneficios
25.3%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 28.5% |
| Tasa de crecimiento de los ingresos | 74.9% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 02 Jun 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Here's Why TCR2 Therapeutics (NASDAQ:TCRR) Must Use Its Cash Wisely
Mar 08
Can TCR2 Therapeutics (NASDAQ:TCRR) Afford To Invest In Growth?
Nov 23TCR² Therapeutics: Betting On A Solid Reversal
Aug 18TCR2 Therapeutics GAAP EPS of -$0.82 misses by $0.02
Aug 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Needs To Drive Business Growth Carefully
Jun 08We Think TCR2 Therapeutics (NASDAQ:TCRR) Can Afford To Drive Business Growth
Jan 11TCR2 Therapeutics: Trading Below Cash
Jan 06TCR2 Therapeutics: Trading Near Cash Value
Oct 12Is There An Opportunity With TCR2 Therapeutics Inc.'s (NASDAQ:TCRR) 26% Undervaluation?
Sep 02TCR2 Therapeutics - Promising Technology And Upside Potential
Jun 15Companies Like TCR2 Therapeutics (NASDAQ:TCRR) Are In A Position To Invest In Growth
Jun 04Who Has Been Selling TCR2 Therapeutics Inc. (NASDAQ:TCRR) Shares?
Feb 19
TCR2 Therapeutics (NASDAQ:TCRR) Is In A Good Position To Deliver On Growth Plans
Dec 28TCR2 Therapeutics share slumps 11%, announces response for Phase 1/2 Trial of TC-210
Dec 14TCR2 Therapeutics reports Q3 results
Nov 12TCR² Therapeutics teams up with ElevateBio to expand TC-210 manufacturing capacity
Nov 10Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2025 | 13 | -235 | N/A | N/A | 1 |
| 12/31/2024 | N/A | -136 | N/A | N/A | 2 |
| 12/31/2023 | N/A | -139 | N/A | N/A | 3 |
| 3/31/2023 | N/A | -163 | -124 | -110 | N/A |
| 12/31/2022 | N/A | -152 | -117 | -101 | N/A |
| 9/30/2022 | N/A | -119 | -120 | -100 | N/A |
| 6/30/2022 | N/A | -115 | -111 | -93 | N/A |
| 3/31/2022 | N/A | -107 | -101 | -89 | N/A |
| 12/31/2021 | N/A | -100 | -93 | -82 | N/A |
| 9/30/2021 | N/A | -91 | -81 | -72 | N/A |
| 6/30/2021 | N/A | -81 | -72 | -63 | N/A |
| 3/31/2021 | N/A | -73 | -72 | -64 | N/A |
| 12/31/2020 | N/A | -67 | -64 | -57 | N/A |
| 9/30/2020 | N/A | -61 | -57 | -54 | N/A |
| 6/30/2020 | N/A | -58 | -57 | -53 | N/A |
| 3/31/2020 | N/A | -53 | -51 | -47 | N/A |
| 12/31/2019 | N/A | -97 | -45 | -41 | N/A |
| 9/30/2019 | N/A | -96 | -41 | -37 | N/A |
| 6/30/2019 | N/A | -100 | -33 | -32 | N/A |
| 3/31/2019 | N/A | -107 | -27 | -27 | N/A |
| 12/31/2018 | N/A | -62 | -20 | -19 | N/A |
| 9/30/2018 | N/A | -55 | -18 | -17 | N/A |
| 12/31/2017 | N/A | -15 | -12 | -12 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: TCRR is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: TCRR is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: TCRR is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: TCRR is forecast to have no revenue next year.
Ingresos de alto crecimiento: TCRR is forecast to have no revenue next year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if TCRR's Return on Equity is forecast to be high in 3 years time